Patient-specific driver gene prediction and risk assessment through integrated network analysis of cancer omics profiles.
Nucleic Acids Res 2015 Apr 20; 43(7):e44.
Extensive and multi-dimensional data sets generated from recent cancer omics profiling projects have presented new challenges and opportunities for unraveling the complexity of cancer genome landscapes. In particular, distinguishing the unique complement of genes that drive tumorigenesis in each patient from a sea of passenger mutations is necessary for translating the full benefit of cancer genome sequencing into the clinic. We address this need by presenting a data integration framework (OncoIMPACT) to nominate patient-specific driver genes based on their phenotypic impact. Extensive in silico and in vitro validation helped establish OncoIMPACT's robustness, improved precision over competing approaches and verifiable patient and cell line specific predictions (2/2 and 6/7 true positives and negatives, respectively). In particular, we computationally predicted and experimentally validated the gene TRIM24 as a putative novel amplified driver in a melanoma patient. Applying OncoIMPACT to more than 1000 tumor samples, we generated patient-specific driver gene lists in five different cancer types to identify modes of synergistic action. We also provide the first demonstration that computationally derived driver mutation signatures can be overall superior to single gene and gene expression based signatures in enabling patient stratification and prognostication. Source code and executables for OncoIMPACT are freely available from http://sourceforge.net/projects/oncoimpact. Nucleic Acids Res 2015 Apr 20; 43(7):e44.
Bertrand, Denis; Chng, Kern Rei; Sherbaf, Faranak Ghazi; Kiesel, Anja; Chia, Burton K H; Sia, Yee Yen; Huang, Sharon K; Hoon, Dave S B; Liu, Edison T.; Hillmer, Axel; and Nagarajan, Niranjan, "Patient-specific driver gene prediction and risk assessment through integrated network analysis of cancer omics profiles." (2015). Faculty Research 2015. 72.